By Dr Induka Abeysena, Portfolio Manager, Genevac
Previous pandemics did not see the rapid, global development of testing kits from labs in their hundreds. However, the emergence of the novel coronavirus, caused by the SARS-CoV-2 viral strain, saw this swift production of testing kits.
In February 2020, the US Food and Drug Administration (FDA) relieved restrictions on laboratories and companies developing their own tests for the SARS-CoV-2 virus. This lift on restrictions led to a quick increase in testing numbers. This increase has proven necessary because in the USA, it could be that between 5 and 20 million tests per day are required in order to achieve effective widespread population testing. While the world works towards developing an effective vaccine for COVID-19, the power to contain the virus remains in testing for infections.
As the novel coronavirus (COVID-19) pandemic is progressing throughout 2020, it has become evident that millions of testing kits are needed internationally every single day. This article explores how a leading provider of tools and technologies for genetic analysis, LGC, Biosearch Technologies, is aiding in the fulfilment of this demand, assisted by evaporation technology from SP Genevac.